Modality
siRNA
MOA
CDK4/6i
Target
B7-H3
Pathway
Hedgehog
MDDGBM
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Dec 2027
Phase 2Current
NCT04735132
2,926 pts·MDD
2018-07→2027-12·Terminated
2,926 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-191.7y awayPh2 Data· MDD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2027-12-19 · 1.7y away
MDD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04735132 | Phase 2 | MDD | Terminated | 2926 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| RHH-1969 | Roche | Approved | BET | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 |